NO20033373L - Forebyggelse av diabetes ved administrering av GnRH- antagonister - Google Patents

Forebyggelse av diabetes ved administrering av GnRH- antagonister

Info

Publication number
NO20033373L
NO20033373L NO20033373A NO20033373A NO20033373L NO 20033373 L NO20033373 L NO 20033373L NO 20033373 A NO20033373 A NO 20033373A NO 20033373 A NO20033373 A NO 20033373A NO 20033373 L NO20033373 L NO 20033373L
Authority
NO
Norway
Prior art keywords
diabetes
administration
prevention
gnrh antagonists
gnrh
Prior art date
Application number
NO20033373A
Other languages
English (en)
Other versions
NO20033373D0 (no
Inventor
Jill D Jacobson
Original Assignee
Childrens Mercy Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Mercy Hospital filed Critical Childrens Mercy Hospital
Publication of NO20033373D0 publication Critical patent/NO20033373D0/no
Publication of NO20033373L publication Critical patent/NO20033373L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20033373A 2001-01-26 2003-07-28 Forebyggelse av diabetes ved administrering av GnRH- antagonister NO20033373L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/771,434 US20020103131A1 (en) 2001-01-26 2001-01-26 Prevention of diabetes by administration of GnRH antagonists
PCT/US2001/041603 WO2002058715A1 (en) 2001-01-26 2001-08-06 Prevention of diabetes by administration of gnrh antagonists

Publications (2)

Publication Number Publication Date
NO20033373D0 NO20033373D0 (no) 2003-07-28
NO20033373L true NO20033373L (no) 2003-09-25

Family

ID=25091800

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033373A NO20033373L (no) 2001-01-26 2003-07-28 Forebyggelse av diabetes ved administrering av GnRH- antagonister

Country Status (12)

Country Link
US (2) US20020103131A1 (no)
EP (1) EP1359931A4 (no)
JP (1) JP2004521114A (no)
KR (1) KR100857628B1 (no)
CN (1) CN1267148C (no)
AU (1) AU2002243197B2 (no)
CA (1) CA2435877C (no)
HK (1) HK1065700A1 (no)
IL (2) IL157119A0 (no)
NO (1) NO20033373L (no)
WO (1) WO2002058715A1 (no)
ZA (1) ZA200305803B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
WO2004056388A1 (en) * 2002-12-19 2004-07-08 Praecis Pharmaceuticals, Inc. Methods of enhancing immune system function in a subject
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
CA2698768A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
RU2010113977A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
TW200950799A (en) * 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物
RU2657444C2 (ru) 2012-06-01 2018-06-13 Ферринг Б.В. Получение дегареликса
WO2016030334A2 (en) 2014-08-26 2016-03-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434136A (en) * 1990-12-14 1995-07-18 Mathias; John R. Treatment of motility disorders with a GNRH analog
US5480969A (en) * 1992-09-15 1996-01-02 The Administrators Of The Tulane Educational Fund Antagonists of LHRH
US5624895A (en) * 1994-02-18 1997-04-29 Georgetown University Medical Center Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
PL342517A1 (en) * 1998-02-23 2001-06-18 Neurocrine Biosciences Methods of treating diabetes employing peptidic insulin analoques

Also Published As

Publication number Publication date
CA2435877A1 (en) 2002-08-01
IL157119A (en) 2012-01-31
KR20040004514A (ko) 2004-01-13
CN1267148C (zh) 2006-08-02
EP1359931A4 (en) 2008-08-13
IL157119A0 (en) 2004-02-08
WO2002058715A1 (en) 2002-08-01
US6875843B2 (en) 2005-04-05
ZA200305803B (en) 2004-07-28
CN1492766A (zh) 2004-04-28
CA2435877C (en) 2011-02-22
NO20033373D0 (no) 2003-07-28
EP1359931A1 (en) 2003-11-12
HK1065700A1 (en) 2005-03-04
US20020103131A1 (en) 2002-08-01
US20030045475A1 (en) 2003-03-06
AU2002243197B2 (en) 2006-09-14
KR100857628B1 (ko) 2008-09-08
JP2004521114A (ja) 2004-07-15

Similar Documents

Publication Publication Date Title
NO20033373L (no) Forebyggelse av diabetes ved administrering av GnRH- antagonister
DK1568367T5 (da) Glucokinase påvirkende forbindelser
GB0126151D0 (en) Administration of medicaments by vaporisation
NO20035087D0 (no) Anvendelse av HMG fragment som anti-inflammatoriske midler
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
MXPA03010007A (es) USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.
FI20011478A (fi) Farmaseuttinen koostumus
NO20033143L (no) Farmasoytisk preparat
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
EE05020B1 (et) Glburiidi ravimkoostis
EE200300589A (et) Ravimkoostised
NO20033205L (no) Terapeutiske kromanforbindelser
DE50209245D1 (de) Neuroprotektives medikament
DK1443938T3 (da) Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20034556L (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
FI20011889A0 (fi) Menetelmä ksylitolin valmistamiseksi
IS7097A (is) Lyfjablanda til að gefa fúlvestrant í vöðva
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
NO20033809L (no) Metronomisk dosering av taxaner
DE60228703D1 (de) Verabreichung von sedativa-hypnotika durch inhalation
TW462220U (en) Improved structure of mousetrap
DE60230502D1 (de) Verabreichung von antimigränemitteln durch inhalation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application